These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17665982)
21. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Zhou SS; Jin JP; Wang JQ; Zhang ZG; Freedman JH; Zheng Y; Cai L Acta Pharmacol Sin; 2018 Jul; 39(7):1073-1084. PubMed ID: 29877320 [TBL] [Abstract][Full Text] [Related]
22. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Thibault PA; Wilson JA Pharmacol Res; 2013 Sep; 75():48-59. PubMed ID: 23541631 [TBL] [Abstract][Full Text] [Related]
23. MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases. Hang P; Guo J; Sun C; Du Z Curr Drug Targets; 2017; 18(4):463-472. PubMed ID: 26926467 [TBL] [Abstract][Full Text] [Related]
24. MicroRNAs as pharmacological targets in diabetes. Mao Y; Mohan R; Zhang S; Tang X Pharmacol Res; 2013 Sep; 75():37-47. PubMed ID: 23810798 [TBL] [Abstract][Full Text] [Related]
25. [MicroRNA and Viral Infection]. Zhao F; Li Y; Duan Z Bing Du Xue Bao; 2015 Mar; 31(2):187-91. PubMed ID: 26164946 [TBL] [Abstract][Full Text] [Related]
26. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Weiler J; Hunziker J; Hall J Gene Ther; 2006 Mar; 13(6):496-502. PubMed ID: 16195701 [TBL] [Abstract][Full Text] [Related]
27. [Human microRNA in norm and pathology]. Rogaev EI; Borinskaia SA; Islamgulov DV; Grigorenko AP Mol Biol (Mosk); 2008; 42(5):751-64. PubMed ID: 18988525 [TBL] [Abstract][Full Text] [Related]
28. Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes. Grieco GE; Brusco N; Licata G; Nigi L; Formichi C; Dotta F; Sebastiani G Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31861156 [TBL] [Abstract][Full Text] [Related]
30. MicroRNA transport in cardiovascular complication of diabetes. Caporali A; Miscianinov V; Saif J; Emanueli C Biochim Biophys Acta; 2016 Dec; 1861(12 Pt B):2111-2120. PubMed ID: 26806392 [TBL] [Abstract][Full Text] [Related]
31. MicroRNAs in the onset and development of cardiovascular disease. Vickers KC; Rye KA; Tabet F Clin Sci (Lond); 2014 Feb; 126(3):183-94. PubMed ID: 24102098 [TBL] [Abstract][Full Text] [Related]
32. MicroRNAs in Cardiovascular Disease. Barwari T; Joshi A; Mayr M J Am Coll Cardiol; 2016 Dec; 68(23):2577-2584. PubMed ID: 27931616 [TBL] [Abstract][Full Text] [Related]
33. Insight into miRNAs related with glucometabolic disorder. Zhang BH; Shen CA; Zhu BW; An HY; Zheng B; Xu SB; Sun JC; Sun PC; Zhang W; Wang J; Liu JY; Fan YQ Biomed Pharmacother; 2019 Mar; 111():657-665. PubMed ID: 30611990 [TBL] [Abstract][Full Text] [Related]
35. A Concise Review of MicroRNA Exploring the Insights of MicroRNA Regulations in Bacterial, Viral and Metabolic Diseases. Naveed A; Ur-Rahman S; Abdullah S; Naveed MA Mol Biotechnol; 2017 Dec; 59(11-12):518-529. PubMed ID: 28884294 [TBL] [Abstract][Full Text] [Related]
36. A human herpesvirus 6A-encoded microRNA: role in viral lytic replication. Nukui M; Mori Y; Murphy EA J Virol; 2015 Mar; 89(5):2615-27. PubMed ID: 25520507 [TBL] [Abstract][Full Text] [Related]
37. MicroRNAs in development and disease. Erson AE; Petty EM Clin Genet; 2008 Oct; 74(4):296-306. PubMed ID: 18713256 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA-based therapeutic approaches in the cardiovascular system. Fiedler J; Gupta SK; Thum T Cardiovasc Ther; 2012 Feb; 30(1):e9-e15. PubMed ID: 20946325 [TBL] [Abstract][Full Text] [Related]
39. Strategies to use microRNAs as therapeutic targets. Krützfeldt J Best Pract Res Clin Endocrinol Metab; 2016 Oct; 30(5):551-561. PubMed ID: 27923450 [TBL] [Abstract][Full Text] [Related]